Success Metrics

Clinical Success Rate

92.3%

Based on 12 completed trials

Completion Rate

92%(12/13)

Active Trials

1(7%)

Results Posted

50%(6 trials)

Terminated

1(7%)

Phase Distribution

Ph phase_1

53%

Ph phase_2

47%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution15 total trials

Phase 1Safety & dosage

8(53.3%)

Phase 2Efficacy & side effects

7(46.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(12)

Terminated(2)

Detailed Status

Completed12

Withdrawn1

Terminated1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

92.3%

Most Advanced

Phase 2

Trials by Phase

Phase 18 (53.3%)

Phase 27 (46.7%)

Trials by Status

withdrawn17%

terminated17%

completed1280%

recruiting17%

Recent Activity

1 active trials

Showing 5 of 15

recruitingphase_2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379

completedphase_1

Clinical Trials (15)

Showing 15 of 15 trials

NCT01042379Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting

NCT01489865Phase 1

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Completed

NCT01009788Phase 2

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Completed

NCT01205828Phase 2

ABT-888 and Temozolomide for Liver Cancer

Terminated

NCT01445522Phase 1

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

Completed

NCT00994071Phase 1

A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

Completed

NCT01051596Phase 2

A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

Completed

NCT01113957Phase 2

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Completed

NCT00804908Phase 2

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Completed

NCT00649207Phase 1

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Completed

NCT00526617Phase 1

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Completed

NCT01085422Phase 1

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Completed

NCT00553189Phase 1

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

Completed

NCT01419548Phase 1

ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems

Withdrawn

NCT01306032Phase 2

Phase II ABT-888 With Cyclophosphamide

Completed

All 15 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 15